Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug 14:4:105.
doi: 10.3389/fneur.2013.00105. eCollection 2013.

Is there a role for treating inflammation in moyamoya disease?: a review of histopathology, genetics, and signaling cascades

Adam M H Young  1 , Surya K Karri, Christopher S Ogilvy, Ninghui Zhao
Affiliations

Is there a role for treating inflammation in moyamoya disease?: a review of histopathology, genetics, and signaling cascades

Adam M H Young et al. Front Neurol. .

Abstract

Moyamoya disease is a slowly progressing steno-occlusive condition affecting the cerebrovasculature. Affecting the terminal internal carotid arteries (ICA) and there branches, bilaterally, a resulting in a fine vascular network in the base of the brain to allow for compensation of the stenosed vessels. While there is obvious evidence of the involvement of inflammatory proteins in the condition, this has historically not been acknowledged as a causal factor. Here we describe the fundamental histopathology, genetics, and signaling cascades involved in moyamoya and debate whether these factors can be linked as causal factor for the condition or whether they are simply a secondary result of the ischemia described in the condition. A particular focus has been placed on the multitude of signaling cascades linked to the condition as these are viewed as having the greatest therapeutic potential. As such we hope to draw some novel insight into potential diagnostic and therapeutic inflammatory targets in the condition.

Keywords: brain; genetics; inflammation; moyamoya.

PubMed Disclaimer

References

    1. Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol (2008) 7(11):1056–66 10.1016/S1474-4422(08)70240-0 - DOI - PubMed
    1. Baba T, Houkin K, Kuroda S. Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry (2008) 79:900–4 10.1136/jnnp.2007.130666 - DOI - PubMed
    1. Wakai K, Tamakoshi A, Ikezaki K, Fukui M, Kawamura T, Aoki R, et al. Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey. Clin Neurol Neurosurg (1997) 99(Suppl 2):S1–5 10.1016/S0303-8467(97)00031-0 - DOI - PubMed
    1. Yonekawa Y, Ogata N, Kaku Y, Taub E, Imhof HG. Moyamoya disease in Europe, past and present status. Clin Neurol Neurosurg (1997) 99(Suppl 2):S58–60 10.1016/S0303-8467(97)00042-5 - DOI - PubMed
    1. Smith ER, Scott RM. Moyamoya: epidemiology, presentation, and diagnosis. Neurosurg Clin N Am (2010) 21(3):543–51 10.1016/j.nec.2010.03.007 - DOI - PubMed